Crohn’s disease is a type of inflammatory bowl disease (IBD) that can take place anywhere in the digestive tract. According to the Centers for Disease Control and Prevention (CDC), prevalence of IBD ...

MetroCreative Inflammatory bowel disease (IBD) affects between 2.4 and 3.1 million people across the United States, according ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

15, 2024 — Scientists uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn's disease. The discovery may help define how to treat patients ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

A device used in South Jersey is a game-changer for people with inflammatory bowel disease as an alternative to invasive ...

Zinpentraxin alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Crohn's Disease (Regional Enteritis).

A new study published recently in the journal Gut shows children with Crohn's who were prescribed anti-TNF (tumor necrosis ...

Nutrients specific to the Mediterranean diet could help with symptom management in inflammatory bowel disease, evidence ...

A study from University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue to experience symptoms ...